Brainstorm Cell Therapeutics Inc. (BCLI) SEC filings
BCLI SEC filings moved a median of 0.00% by the close. BCLI SEC filings — 10-K, 10-Q, 8-K and the rest — each read against the price at its own news timestamp. Back to the BCLI overview →
79 measured BCLI SEC filing events.
Where these BCLI SEC filings landedvs 79 measured BCLI SEC filing reactions
| Middle 50% of BCLI SEC filing reactions | -4.66% to +5.88% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 79 |
Point-in-time · zero look-ahead
Half of the 79 BCLI SEC filing events with a measured close landed between -4.66% and +5.88%; 49% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q BRAINSTORM CELL THERAPEU For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +9.64% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Aug 14 | SEC filing · Form 8-K | +0.00% | +9.64% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jul 24 | SEC filing · Form 8-K | +0.00% | +0.00% | |
| Form EFFECT BRAINSTORM CELL THERAPEU | SEC filing · Form EFFECT | +0.00% | +1.16% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: May 25 | SEC filing · Form 8-K | +0.00% | +0.00% | |
| Form S-1 BRAINSTORM CELL THERAPEU | SEC filing · Form S-1 | +0.00% | -2.32% | |
| Form S-8 BRAINSTORM CELL THERAPEU | SEC filing · Form S-8 | +0.00% | -2.32% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -1.41% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: May 15 | SEC filing · Form 8-K | +0.00% | -1.41% | |
| Form 10-K BRAINSTORM CELL THERAPEU For: Dec 31 | SEC filing · Form 10-K | +0.67% | +6.24% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Mar 31 | SEC filing · Form 8-K | +0.67% | +6.24% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Feb 24 | SEC filing · Form 8-K | +0.00% | +1.53% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Feb 09 | SEC filing · Form 8-K | +0.00% | +2.15% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jan 05 | SEC filing · Form 8-K | +0.00% | -10.76% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +10.82% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Nov 10 | SEC filing · Form 8-K | +0.00% | +10.82% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Oct 31 | SEC filing · Form 8-K | +0.00% | +4.69% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Jun 30 | SEC filing · Form 10-Q | -5.80% | -12.54% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Aug 14 | SEC filing · Form 8-K | -5.80% | -12.54% | |
| Form RW BRAINSTORM CELL THERAPEU | SEC filing · Form RW | +0.28% | +0.72% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jul 16 | SEC filing · Form 8-K | +0.00% | +20.00% | |
| Form S-8 BRAINSTORM CELL THERAPEU | SEC filing · Form S-8 | +0.86% | -1.72% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jun 25 | SEC filing · Form 8-K | +0.14% | -6.03% | |
| Form S-3 BRAINSTORM CELL THERAPEU | SEC filing · Form S-3 | +0.14% | -6.03% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jun 16 | SEC filing · Form 8-K | -1.20% | -4.80% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: May 19 | SEC filing · Form 8-K | -5.39% | -3.13% | |
| Form ARS BRAINSTORM CELL THERAPEU For: Dec 31 | SEC filing · Form ARS | +0.86% | +13.79% | |
| Form DEF 14A BRAINSTORM CELL THERAPEU For: Jun 25 | SEC filing · Form DEF | +0.86% | +13.79% | |
| Form DEFA14A BRAINSTORM CELL THERAPEU | SEC filing · Form DEFA14A | +0.86% | +13.79% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Mar 31 | SEC filing · Form 10-Q | +0.86% | +13.79% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: May 15 | SEC filing · Form 8-K | +0.86% | +13.79% | |
| Form PRE 14A BRAINSTORM CELL THERAPEU For: May 06 | SEC filing · Form PRE | +0.00% | -2.42% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Apr 20 | SEC filing · Form 8-K | +0.00% | +3.74% | |
| Form 10-K BRAINSTORM CELL THERAPEU For: Dec 31 | SEC filing · Form 10-K | -2.92% | +5.88% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Mar 31 | SEC filing · Form 8-K | -2.92% | +5.88% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Mar 25 | SEC filing · Form 8-K | +0.00% | +0.75% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jan 21 | SEC filing · Form 8-K | -4.35% | -7.39% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jan 15 | SEC filing · Form 8-K | +1.00% | -0.50% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Sep 30 | SEC filing · Form 10-Q | +3.09% | +14.15% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Nov 14 | SEC filing · Form 8-K | +3.09% | +14.15% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Oct 29 | SEC filing · Form 8-K | -0.49% | -1.03% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Oct 01 | SEC filing · Form 8-K | -0.30% | -3.56% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Sep 30 | SEC filing · Form 8-K | -0.28% | -19.02% | |
| Form EFFECT BRAINSTORM CELL THERAPEU | SEC filing · Form EFFECT | +0.85% | +3.46% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Sep 26 | SEC filing · Form 8-K | +3.29% | -7.33% | |
| Form S-3/A BRAINSTORM CELL THERAPEU | SEC filing · Form S-3 | +0.00% | +0.33% | |
| Form S-3 BRAINSTORM CELL THERAPEU | SEC filing · Form S-3 | +0.04% | -2.46% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Sep 16 | SEC filing · Form 8-K | -0.18% | -2.89% | |
| Form EFFECT BRAINSTORM CELL THERAPEU | SEC filing · Form EFFECT | -3.29% | +3.47% | |
| Form S-3 BRAINSTORM CELL THERAPEU | SEC filing · Form S-3 | +3.32% | +2.77% | |
| Form ARS BRAINSTORM CELL THERAPEU For: Dec 31 | SEC filing · Form ARS | -2.06% | +6.41% | |
| Form DEF 14A BRAINSTORM CELL THERAPEU For: Sep 16 | SEC filing · Form DEF | -2.06% | +6.41% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Jun 30 | SEC filing · Form 10-Q | +0.03% | -4.66% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Aug 14 | SEC filing · Form 8-K | +0.03% | -4.66% | |
| Form PRER14A BRAINSTORM CELL THERAPEU | SEC filing · Form PRER14A | -1.17% | -7.94% | |
| Form PRE 14A BRAINSTORM CELL THERAPEU For: Sep 16 | SEC filing · Form PRE | -3.19% | -7.36% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jul 29 | SEC filing · Form 8-K | +0.00% | +1.60% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jul 18 | SEC filing · Form 8-K | +0.22% | -2.21% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jun 27 | SEC filing · Form 8-K | -2.86% | -10.69% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jun 26 | SEC filing · Form 8-K | +1.35% | -2.60% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jun 19 | SEC filing · Form 8-K | -1.76% | -6.80% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Jun 03 | SEC filing · Form 8-K | -1.89% | -17.11% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Mar 31 | SEC filing · Form 10-Q | +1.94% | -6.92% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: May 01 | SEC filing · Form 8-K | +8.13% | +1.35% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Apr 16 | SEC filing · Form 8-K | +2.86% | +3.01% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Apr 10 | SEC filing · Form 8-K | +3.39% | -2.19% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Apr 09 | SEC filing · Form 8-K | -5.48% | -20.20% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Apr 02 | SEC filing · Form 8-K | +1.39% | -2.92% | |
| Form 10-K BRAINSTORM CELL THERAPEU For: Dec 31 | SEC filing · Form 10-K | +0.08% | +21.59% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Apr 01 | SEC filing · Form 8-K | +0.08% | +21.59% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Dec 18 | SEC filing · Form 8-K | +2.37% | +1.58% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Nov 20 | SEC filing · Form 8-K | -3.78% | +15.15% | |
| Form DEFA14A BRAINSTORM CELL THERAPEU | SEC filing · Form DEFA14A | -7.25% | -7.11% | |
| Form 10-Q BRAINSTORM CELL THERAPEU For: Sep 30 | SEC filing · Form 10-Q | -0.54% | +0.22% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Nov 14 | SEC filing · Form 8-K | -0.54% | +0.22% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Nov 06 | SEC filing · Form 8-K | -1.90% | +4.48% | |
| Form DEF 14A BRAINSTORM CELL THERAPEU For: Dec 18 | SEC filing · Form DEF | +0.00% | -4.47% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Nov 01 | SEC filing · Form 8-K | -1.69% | -13.82% | |
| Form 8-K BRAINSTORM CELL THERAPEU For: Oct 18 | SEC filing · Form 8-K | +0.30% | -8.01% |
Keep exploring
More BCLI: earnings → · analyst actions → · BCLI overview →
Other Healthcare names and their SEC filings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | 664 | -0.07% | 48% |
| UroGen Pharma Ltd. - Ordinary Shares (URGN) | 664 | +0.13% | 53% |
| OPHTHOTECH CORP COMMON (OPHT) | 660 | -0.20% | 43% |
| Gritstone bio, Inc. (GRTS) | 659 | -0.01% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its SEC filings — that is what the link opens.